ES2106360T3 - Formulaciones farmaceuticas de aerosol que contienen dipropionato de beclometasona. - Google Patents

Formulaciones farmaceuticas de aerosol que contienen dipropionato de beclometasona.

Info

Publication number
ES2106360T3
ES2106360T3 ES93917355T ES93917355T ES2106360T3 ES 2106360 T3 ES2106360 T3 ES 2106360T3 ES 93917355 T ES93917355 T ES 93917355T ES 93917355 T ES93917355 T ES 93917355T ES 2106360 T3 ES2106360 T3 ES 2106360T3
Authority
ES
Spain
Prior art keywords
aerosol
pharmaceutical formulations
aerosol containing
beclometasone dipropionate
inhalation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93917355T
Other languages
English (en)
Inventor
Philip John Neale
Anthony James Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ES2106360T3 publication Critical patent/ES2106360T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

ESTA INVENCION ES RELATIVA A FORMULACIONES PARA AEROSOL DE USO PARA LA ADMINISTRACION DE MEDICAMENTOS POR INHALACION, EN PARTICULAR UNA FORMULACION FARMACEUTICA PARA AEROSOL QUE COMPRENDE: (A) MONOHIDRATO DE DIPROPIONATO DE BECLOMETASONA, SIENDO EL TAMAÑO DE PARTICULA DE SUSTANCIALMENTE LA TOTALIDAD DEL MONOHIDRATO MENOR DE 20 MICRAS; (B) AL MENOS 0,015 % DE PESO DE LA FORMULACION DE AGUA ADICIONAL AL AGUA DE CRISTALIZACION ASOCIADA CON DICHO MONOHIDRATO; Y (C) UN PROPELENTE DE FLUOROCARBONO O DE CLOROFLUOROCARBONO QUE CONTIENE HIDROGENO. TAMBIEN SE DESCRIBE UN METODO DE TRATAR DESORDENES RESPIRATORIOS LOS CUALES COMPRENDEN ADMINISTRACION POR INHALACION DE UNA CANTIDAD EFECTIVA DE UNA FORMULACION FARMACEUTICA PARA AEROSOL COMO SE DEFINE EN LA MEMORIA.
ES93917355T 1992-02-06 1993-02-02 Formulaciones farmaceuticas de aerosol que contienen dipropionato de beclometasona. Expired - Lifetime ES2106360T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929202519A GB9202519D0 (en) 1992-02-06 1992-02-06 Medicaments

Publications (1)

Publication Number Publication Date
ES2106360T3 true ES2106360T3 (es) 1997-11-01

Family

ID=10709929

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93917355T Expired - Lifetime ES2106360T3 (es) 1992-02-06 1993-02-02 Formulaciones farmaceuticas de aerosol que contienen dipropionato de beclometasona.

Country Status (30)

Country Link
US (2) US5695744A (es)
EP (1) EP0625046B1 (es)
JP (1) JP3675474B2 (es)
CN (1) CN1048394C (es)
AP (1) AP419A (es)
AT (1) ATE157875T1 (es)
AU (1) AU667074B2 (es)
BG (1) BG61862B1 (es)
CA (1) CA2128688A1 (es)
CZ (1) CZ281942B6 (es)
DE (1) DE69313825T2 (es)
DK (1) DK0625046T3 (es)
ES (1) ES2106360T3 (es)
GB (1) GB9202519D0 (es)
GE (1) GEP19991820B (es)
GR (1) GR3025363T3 (es)
HU (2) HUT68986A (es)
IL (1) IL104628A (es)
IS (1) IS1622B (es)
MX (1) MX9300620A (es)
MY (1) MY108748A (es)
NO (1) NO306453B1 (es)
NZ (1) NZ246889A (es)
OA (1) OA10091A (es)
RO (1) RO118173B1 (es)
RU (1) RU2120285C1 (es)
SK (1) SK279291B6 (es)
TW (1) TW299234B (es)
WO (1) WO1993015741A1 (es)
ZA (1) ZA93800B (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919435A (en) * 1990-11-09 1999-07-06 Glaxo Group Limited Aerosol formulation containing a particulate medicament
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
JP3026841B2 (ja) 1991-12-12 2000-03-27 グラクソ、グループ、リミテッド 医 薬
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
DK0717987T3 (da) 1991-12-18 2001-11-12 Minnesota Mining & Mfg Suspension-aerosol-formuleringer
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
US5833950A (en) * 1992-07-31 1998-11-10 Glaxo Group Limited Aerosol formulations containing beclomethasone dipropionate-1, 1, 1, 2-tetrafluoroethane solvate
GB9404945D0 (en) * 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
JP4155594B2 (ja) * 1994-12-22 2008-09-24 アストラゼネカ・アクチエボラーグ エアゾール製剤
US6013245A (en) * 1995-01-26 2000-01-11 Glaxo Group Limited Aerosol formulation containing beclomethasone dipropionate and 1,1,1,2,3,3,3-heptafluoro-n-propane as propellant
US5874481A (en) * 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
BR9609307B1 (pt) 1995-06-27 2010-03-09 preparação farmacêutica para produção de aerossóis inaláveis isentos de propelentes para administração nos pulmões, bem como aerossol compreendendo a mesma.
ES2175676T3 (es) * 1997-01-14 2002-11-16 Lohmann Therapie Syst Lts Sistema terapeutico expansible de retencion gastrica con liberacion controlada de principio activo en el tracto gastrointestinal.
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
SK122199A3 (en) * 1997-03-18 2000-12-11 Basf Ag Methods and compositions for modulating responsiveness to corticosteroids
US6129905A (en) * 1997-04-21 2000-10-10 Aeropharm Technology, Inc. Aerosol formulations containing a sugar as a dispersant
US5891420A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe triancinolone acetonide aerosol formulations for oral inhalation
US5891419A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe flunisolide aerosol formulations for oral inhalation
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6946117B1 (en) * 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6598603B1 (en) * 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
WO1999044594A1 (fr) * 1998-03-05 1999-09-10 Nippon Shinyaku Co., Ltd. Emulsions huileuses destinees a etre administrees par inhalation
TWI243687B (en) * 1998-04-21 2005-11-21 Teijin Ltd Pharmaceutical composition for application to mucosa
US6458338B1 (en) 1998-09-22 2002-10-01 Aeropharm Technology Incorporated Amino acid stabilized medicinal aerosol formulations
US6136294C1 (en) * 1998-09-22 2002-09-24 Aeropharm Technology Inc Amino acid stabilized medical aerosol formulation
IT1303692B1 (it) * 1998-11-03 2001-02-23 Chiesi Farma Spa Procedimento per la preparazione di sospensioni di particelle difarmaci da somministrare per inalazione.
US7074388B2 (en) * 1998-12-10 2006-07-11 Kos Life Science, Inc. Water stabilized medicinal aerosol formulation
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
US6261539B1 (en) * 1998-12-10 2001-07-17 Akwete Adjei Medicinal aerosol formulation
US6540982B1 (en) * 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
US6540983B1 (en) 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
US6565833B1 (en) 2000-05-01 2003-05-20 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6548049B1 (en) 2000-05-01 2003-04-15 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6447750B1 (en) 2000-05-01 2002-09-10 Aeropharm Technology Incorporated Medicinal aerosol formulation
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
PT1280520E (pt) 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
WO2002007672A2 (en) * 2000-07-19 2002-01-31 Aeropharm Technology, Inc. A medicinal aerosol formulation
AU2001278115A1 (en) * 2000-08-04 2002-02-18 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
US6455028B1 (en) 2001-04-23 2002-09-24 Pharmascience Ipratropium formulation for pulmonary inhalation
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
TWI324518B (en) 2001-12-19 2010-05-11 Nektar Therapeutics Pulmonary delivery of aminoglycosides
EP1415647A1 (en) * 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. "Long-acting beta-2 agonists ultrafine formulations"
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
AU2007231727B2 (en) * 2002-09-03 2010-12-16 Kos Life Sciences, Inc. Water stabilized medicinal aerosol formulation
ES2304616T3 (es) * 2003-03-20 2008-10-16 Boehringer Ingelheim Pharmaceuticals Inc. Formulacion para un inhalador con dosis medida utilizando hidro-fluoro-alcanos como propulsores.
US20040191176A1 (en) * 2003-03-28 2004-09-30 Kaplan Leonard W Formulations for treatment of pulmonary disorders
AU2004270171A1 (en) * 2003-08-29 2005-03-17 Glaxo Group Limited Pharmaceutical metered dose inhaler and methods relating thereto
AR041873A1 (es) * 2003-10-30 2005-06-01 Pablo Cassara Srl Lab Una formulacion farmaceutica en aerosol adecuada para la inhalacion oral o nasal que contienen glucocorticoides en solucion estable al almacenamiento; un metodo para estabilzar formulaciones y uso de un agente estabilizante
US20050238632A1 (en) * 2004-04-23 2005-10-27 Alburty David S Propellant formulations
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
BRPI0512878A (pt) 2004-07-02 2008-04-15 Boehringer Ingelheim Int formulações de suspensão de aerossol, com tg 227 ea ou tg 134 a como agente propulsor
GB0417481D0 (en) * 2004-08-05 2004-09-08 Etiologics Ltd Combination therapy
SI1845994T1 (sl) 2005-02-11 2009-06-30 Argenta Discovery Ltd Kombinacija metilksantinskih spojin in steroidov za zdrvljenje kroničnih respiratornih bolezni
US9084799B2 (en) 2005-02-11 2015-07-21 Pulmagen Therapeutics (Synergy) Limited Inhaled combination therapy
DE102006017320A1 (de) 2006-04-11 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolsuspensionsformulierungen mit TG 227 ea oder TG 134 a als Treibmittel
US20070286814A1 (en) * 2006-06-12 2007-12-13 Medispray Laboratories Pvt. Ltd. Stable aerosol pharmaceutical formulations
PL2425820T3 (pl) 2007-02-11 2015-08-31 Map Pharmaceuticals Inc Sposób terapeutycznego stosowania dhe w celu umożliwienia szybkiego złagodzenia migreny przy jednoczesnym zminimalizowaniu profilu działań niepożądanych
RU2504402C1 (ru) * 2012-11-20 2014-01-20 Шолекс Девелопмент Гмбх Ингаляционный состав в форме аэрозоля для лечения бронхиальной астмы и хронической обструктивной болезни легких

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI63672C (fi) * 1980-05-19 1983-08-10 Orion Yhtymae Oy Foerfarande foer framstaellning av en blandning av beklometasondipropionat och triklorfluormetan eller diklordifluormetan
KR890000664B1 (ko) * 1981-10-19 1989-03-22 바리 안소니 뉴우샘 미분된 베클로메타손 디프로피오네이트 일수화물의 제조방법
GB2107715B (en) * 1981-10-19 1985-11-13 Glaxo Group Ltd Micronised beclomethasone dipropionate monohydrate and powder inhalation compositions containing it
GB8432063D0 (en) * 1984-12-19 1985-01-30 Riker Laboratories Inc Physically modified steroids
ATE114112T1 (de) * 1990-10-18 1994-12-15 Minnesota Mining & Mfg Aerosolzubereitung, die beclometason 17,21- dipropionat enthält.

Also Published As

Publication number Publication date
MY108748A (en) 1996-11-30
CZ184694A3 (en) 1995-03-15
SK92494A3 (en) 1995-04-12
NO942923L (no) 1994-08-05
AP9300484A0 (en) 1993-04-30
IL104628A0 (en) 1993-06-10
SK279291B6 (sk) 1998-09-09
GR3025363T3 (en) 1998-02-27
RO118173B1 (ro) 2003-03-28
ATE157875T1 (de) 1997-09-15
IS3974A (is) 1993-08-07
DK0625046T3 (da) 1998-04-27
CN1078633A (zh) 1993-11-24
TW299234B (es) 1997-03-01
EP0625046A1 (en) 1994-11-23
HK1009588A1 (en) 1999-06-04
US5695744A (en) 1997-12-09
NZ246889A (en) 1996-11-26
OA10091A (en) 1996-12-18
HU211696A9 (en) 1995-12-28
AU3452593A (en) 1993-09-03
JP3675474B2 (ja) 2005-07-27
DE69313825T2 (de) 1998-02-05
WO1993015741A1 (en) 1993-08-19
CA2128688A1 (en) 1993-08-19
ZA93800B (en) 1993-10-06
RU2120285C1 (ru) 1998-10-20
AU667074B2 (en) 1996-03-07
JPH07503476A (ja) 1995-04-13
AP419A (en) 1995-10-24
HUT68986A (en) 1995-08-28
CZ281942B6 (cs) 1997-04-16
HU9402301D0 (en) 1994-10-28
BG61862B1 (bg) 1998-08-31
IS1622B (is) 1996-10-18
IL104628A (en) 1998-12-27
NO942923D0 (es) 1994-08-05
NO306453B1 (no) 1999-11-08
CN1048394C (zh) 2000-01-19
MX9300620A (es) 1993-08-01
GB9202519D0 (en) 1992-03-25
BG98897A (bg) 1995-02-28
EP0625046B1 (en) 1997-09-10
GEP19991820B (en) 1999-11-05
US5688782A (en) 1997-11-18
DE69313825D1 (de) 1997-10-16

Similar Documents

Publication Publication Date Title
MX9300620A (es) Formulacion farmaceutica en aerosol e inhalador para la administracion de dipropionato de beclometasona.
MX9207200A (es) Formulacion farmaceutica en aerosol, bote para suministrar dicha formulacion e inhalador de dosis dosificada que comprende dicho bote.
ES2123576T3 (es) Medicamentos.
ES2180592T3 (es) Formulaciones en aerosol libres de clorofluorocarbonos.
ES2113444T3 (es) Medicamentos.
CO5031245A1 (es) Inhaladores de dosis regulada a presion y formulaciones farmaceuticas de aerosol
ES2176355T3 (es) Formulaciones de aerosol de peptidos y proteinas.
AR009231A1 (es) Formulaciones en aerosol de formoterol.
ES2061252T3 (es) Agente antitusivo y regulador de la mucosa, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
CO5060522A1 (es) Administracion de un agente activo en aerosol
MX9304585A (es) Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata.
DK0656207T3 (da) Aerosolformuleringer uden chlorfluorcarbonforbindelser
ES2179831T3 (es) Liberacion en los pulmones de fragmentos activos de hormona paratiroidiana.
ES2047171T3 (es) Sistema terapeutico para la administracion transdermica o transmucosa de sustancias activas, asi como su aplicacion.
ES2093735T3 (es) Derivados de melatonina para uso en la terapia de trastornos del sueño y en medicacion preanestesica.
BR9916865A (pt) Composição farmacêutica em aerossol contendohfa 227 e hfa 134a
PE30399A1 (es) Producto para pulverizar sobre el cabello
ES2063146T3 (es) Composiciones farmaceuticas que contienen acido n-(3,4-dimetoxicinamoil)-antranilico.
AR013614A1 (es) Nueva composicion que comprende una combinacion de esteroides, un kit que la contiene, el uso de la misma, el uso de dicho kit de formoterol y debudesonida en la fabricacion de un medicamento
ES2052603T3 (es) Derivados de bencimidazol, procedimiento para su produccion y composicion farmaceutica que los contienen.
ES2134634T3 (es) Composiciones farmaceuticas y dispositivos para su administracion.
ES2192256T3 (es) Soluciones farmaceuticas inyectables que contienen paracetamol y combinaciones de paracetamol con otras sustancias activas.
PT92002A (pt) Processo para a preparacao de formulacoes dispensaveis que contem diclofenac
BR0317340A (pt) Formulações de hfc em solução contendo tiotrópio
BR9916830A (pt) Formulações aerossóis farmacêuticas contendo fluoroalcanos e budesonide

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 625046

Country of ref document: ES